- Full estradiol suppression with GnRH antagonists alone can result in hypoestrogenic side effects such as hot flushes and loss of BMD1,2
- Combining add-back therapy (ABT) with a GnRH antagonist, has been proven to avoid the hypoestrogenic effects associated with GnRH antagonism alone.3,4 For example, the incidence of VMS and bone loss are significantly reduced to placebo levels with combined GnRH antagonism and ABT1,3,4
- The Summary of Product Characteristics for any available GnRH antagonist clearly shows the incidence of potential issues like VMS and BMD loss, observed in the respective Phase 3 trials3,5
1. Osuga Y et al. Obs & Gynecol 2019; 133(3): 423-433.
2. Barbieri RL. Am J Obstet Gynecol 1992;166:740–745.
3. Relugolix Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/ryeqo-epar-product-information_en.pdf
4. Al Hendy A et al. N Eng J Med 2021; 384:630-642.
5. Linzagolix Summary of Product Characteristics. https://www.ema.europa.eu/en/medicines/human/EPAR/yselty.
